



Company Overview

Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. The company's patented "Veto-Cell" technology represents a major breakthrough in immune system management - safe and selective "tolerizing" of immune response. This technology addresses one of the most fundamental challenges in human immunology: how to tune immune response so that it tolerates specific "desirable" foreign cells while continuing to attack all other potential threats.

Our mission is to revolutionize the fields of transplantation, cancer treatment and reversal of vital organ disease, utilizing our breakthrough immune tolerance and organ regeneration technologies, in order to save lives and fulfill the inspiring promise of immunotherapy.

Cell Source to Present at the LD Micro Main Event

Nov 27 2015, 9:34 AM EST

Cell Source's Megadose Drug Combination Treats First Patient

Nov 11 2015, 8:51 AM EST

Inaugural Scientific Advisory Board Summit JV Pharma Collaboration Initiative

Nov 4 2015, 9:14 AM EST

Cell Source, Inc.

57 W 57th Street
Suite 400
New York, NY 10019

Stock Overview

Symbol	CLCS
Exchange	OTCQB
Market Cap	29.7m
Last Price	\$1.00
52-Week	\$0.4101 - \$1.56

10/29/2020 11:23 AM EDT

Investor Relations

T: 888-315-4650
info@cell-source.com

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.